UNSPSC 51292021: Dapoxetine hydrochloride

This classification denotes a selective serotonin reuptake inhibitor and antidepressant agent with the molecular formula C21H23NO.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U4OHT63MRI, chemically known as (+)-(s)-n,n-dimethyl-alpha-(2-(1-naphthyloxy)ethyl)benzylamine hydrochloride but more generally known as dapoxetine hydrochloride, which bears US NIH Compound Identifier 71352.

UNSPSC 51292021 Dapoxetine hydrochloride (Commodity) does not match the work actually being solicited under this code in recent state and local procurement. The three most recent opportunities—a Seminole County, Florida IFB for naloxone and drug deactivation systems; a Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription programs; and a Minnesota Multistate Cooperative Purchasing Alliance RFP for generic pharmaceuticals and OTC products—focus on naloxone, prescription fulfillment infrastructure, and broad-spectrum generic pharmaceutical procurement. None of these solicitations reference dapoxetine hydrochloride, a pharmaceutical active ingredient used in certain therapeutic products. The code shows little relevant recent activity, and the tagging appears to reflect a data classification issue rather than actual procurement demand for this specific ingredient.

Without recent opportunities specifically purchasing dapoxetine hydrochloride, the code does not provide actionable signals for business development at state and local level. Vendors in pharmaceutical manufacturing or ingredient supply should verify coding accuracy through direct contact with relevant issuing bodies before pursuing opportunities tagged under this code.